

Supplemental 4. PFT results from studies reporting spirometry

Ref.	Location	Group	N (Total)	Ever smoker (%)	COPD (%)	Br. (%)	Asthma (%)	COPD + Br. (%)	N (PFT)	FEV ₁ (%) predicted)	G 1 (%)	G 2 (%)	G 3 (%)	G 4 (%)	FVC (%) predicted)	FEV ₁ /FVC	FEV ₁ /FVC < 0.70	BDR (%)	N (D/T)	DLCO (% predicted)	TLC (%) predicted)
14	TEHS	Total	380	93	100	49.9	32.6	49.9	175	42.3±18.2	-	-	-	-	56.4±17.2	0.56±0.17	78.9	28.7	39	59.3±35	77.5±26.1
15	TEHS	Total	150	54.6	49	19	49	-	150	55.2±20.5	1.9	31.5	35.2	31.5	61±15.8	0.71±0.16	36	-	71	64±19.7	70.1±18.2
7	TEHS	Total	258	74.4	64.7	100	17.1	64.7	258	36.3±17.9	-	-	-	-	50.3±17.9	0.59±0.19	-	-	-	-	-
30	TEHS	Total	258	90.8	100	31.8	32.2	31.8	122	42±18.6	-	-	-	-	56.7±16.6	0.56±0.15	77.1	29.3	-	-	-
	TEHS	No Br.	176	93.6	100	0	31.6	0	85	43.3±19.2	-	-	-	-	57.8±16.4	0.56±0.16	75.3	25.7	-	-	-
	TEHS	Br.	82	84.6	100	100	33.3	100	37	39±16.7	-	-	-	-	53.9±16.6	0.56±0.12	81.1	35.7	-	-	-
31	TEHS	Total	240	91.7	100	-	-	-	240	41.4±16.2	-	-	-	-	58.8±16.6	0.57±0.13	100	-	-	-	-
32	TEHS	GOLD	238	92	70	22	-	-	238	43.6±17.3	2	33	41	24	58.9±17.1	0.57±0.1	100	-	-	-	-
	TEHS	GLI	238	93	68	22	-	-	238	43.7±16.8	7	18	35	40	59.3±16.6	0.57±0.1	100	-	-	-	-
33	TEHS	Total	115	89.6	39.3	22.3	-	11.6	115	56.4±15.1	-	-	-	-	63.4±13.4	0.7±0.13	-	-	-	-	-
	TEHS	No CAD	59	-	-	-	-	-	59	67.1±12.2	-	-	-	-	69±11.1	0.77±0.09	-	-	-	-	-
	TEHS	CAD	56	-	-	-	-	-	56	45.1±11.4	-	-	-	-	57.4±10.8	0.62±0.11	-	-	-	-	-
34	TEHS	F. no CAD	179	81	0	0	-	0	179	63.6±18.4	-	-	-	-	65.7±15.3	0.78±0.12	21.2	15.6	-	-	-
	TEHS	F. CAD	92	88	71.6	41.2	-	13	92	50.7±19.3	-	-	-	-	59.3±15.5	0.67±0.12	45.6	21.7	-	-	-
	TEHS	M. no CAD	111	83.4	0	0	-	0	111	66.2±18.5	-	-	-	-	67.5±16.1	0.77±0.11	20.7	12.6	-	-	-
	TEHS	M. CAD	103	96.2	81.5	44.7	-	26.2	103	47.6±19	-	-	-	-	58.8±16.4	0.61±0.12	68.9	29.1	-	-	-
35	TEHS	Total	742	83.4	25.5	15.9	16.6	8.9	742	-	-	-	-	-	-	-	32.1	16.6	-	-	-
	TEHS	BDR	123	88.6	36.2	18.6	100	8.8	123	51.3±13.5	-	-	-	-	61.7±12.3	0.65±0.13	59.4	100	-	-	-
	TEHS	No BDR	619	82.4	23.2	15.3	0	8.9	619	-	-	-	-	-	-	-	26.7	0	-	-	-
37	TEHS	Normal	63	81	0	0	-	0	63	64.6±11.8	-	-	-	-	65.3±10.8	0.79±0.09	-	10	-	-	-
	TEHS	COPD	74	97	100	0	-	0	74	48.9±13	-	-	-	-	62±11.4	0.61±0.12	-	19	-	-	-
	TEHS	Br.	40	87	0	100	-	0	40	50.7±10.8	-	-	-	-	54.2±10.4	0.71±0.10	-	10	-	-	-
	TEHS	COPD + Br.	35	97	100	100	-	100	35	39.6±10	-	-	-	-	53.2±9.5	0.57±0.09	-	11	-	-	-
39	TEHS	Total	59	88.1	100	13.8	24.1	13.8	53	43.4±17.8	1.9	24.5	24.5	28.3	58.9±18.9	0.58±0.15	77.8	-	-	-	-
8	Central AU	Br. case	85	67.5	-	100	-	-	46	29±13	-	-	-	-	40.3±12.2	0.58±0.20	74.1	-	-	-	-
45	Central AU	Br. case	80	63.8	10	100	1.3	10	38	36.1±17	-	-	-	-	45.8±14.1	0.64±0.16	-	-	-	-	-
46	Central AU	Total	415	54	-	6.5	-	-	-	-	-	-	-	-	-	-	7.2	-	-	-	-
48	N. QLD	Total	1117	77	35	4	34	-	1117	72±22	19	55	21	5	80±19	0.73±0.13	-	-	-	81±24	-
50	Kimberley	Total	328	68.3	4.9	-	21	-	253	-	1.2	4.8	2.4	-	-	-	-	3.1	-	-	-
51	Kimberley	Total	23	82	-	100	-	-	5	49±5.8	-	-	-	-	-	-	-	-	-	-	-
Percentage predicted values obtained utilising NHANES III dataset with no ethnic correction. Abbreviations: AU, Australia; BDR , Bronchodilator response; Br. , Bronchiectasis; CAD , Chronic airway disease (bronchiectasis or COPD); COPD , Chronic obstructive pulmonary disease; D/T , DLCO or TLC available; DLCO , Diffusing capacity of carbon monoxide; F. , Female; FEV₁ , Forced expiratory volume in one second; FVC , Forced vital capacity; G 1/2/3/4 , GOLD stages 1-4 (% of patients in each category); GLI , Global lung function initiative; GOLD , Global initiative for chronic obstructive lung disease; M. , Male; N. QLD , North Queensland; PFT , Pulmonary function test; Ref. , Reference; TEHS , Top end health service; TLC , Total lung capacity.																					